|Manufacturer:||GlaxoSmithKline manufactures Naramig.|
|Uses:||The uses of Naramig include:|
Product Origin: EU (Turkey)
This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.
Naratriptan Tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive Naratriptan Tablets. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e. g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal's variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease.
Because Naratriptan Tablets may increase blood pressure, they should not be given to patients with uncontrolled hypertension
Naratriptan Tablets are contraindicated in patients with severe renal impairment (creatinine clearance <15 mL/ min)
Naratriptan Tablets are contraindicated in patients with severe hepatic impairment (Child-Pugh grade C)
Naratriptan Tablets should not be administered to patients with hemiplegic or basilar migraine.
Naratriptan Tablets should not be used within 24 hours of treatment with another 5-HT1 agonist, an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide.
Naratriptan Tablets are contraindicated in patients with hypersensitivity to naratriptan or any of the components.